These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32735793)

  • 21. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
    Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
    Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab.
    Bhutani D; Assal A; Mapara MY; Prinzing S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):e155-e157. PubMed ID: 32098724
    [No Abstract]   [Full Text] [Related]  

  • 25. [Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].
    Fujimori C; Hagino T; Osanai S; Sano S; Saga R; Hidai H; Kurimoto M; Murai Y; Akiyama H; Motomura S
    Rinsho Ketsueki; 2022; 63(12):1626-1632. PubMed ID: 36653134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA.
    Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D
    Blood Cancer J; 2023 Jul; 13(1):113. PubMed ID: 37495597
    [No Abstract]   [Full Text] [Related]  

  • 27. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
    Martin TG
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.
    Gavriilaki E; Dalampira D; Theodorakakou F; Liacos CI; Kanellias N; Eleutherakis-Papaiakovou E; Terpos E; Gavriatopoulou M; Verrou E; Triantafyllou T; Sevastoudi A; Koravou EE; Touloumenidou T; Varelas C; Papalexandri A; Sakellari I; Dimopoulos MA; Kastritis E; Katodritou E
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
    Nguyen MN; Nayernama A; Jones SC; Kanapuru B; Gormley N; Waldron PE
    Am J Hematol; 2020 Sep; 95(9):E218-E222. PubMed ID: 32291777
    [No Abstract]   [Full Text] [Related]  

  • 32. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma.
    Hamad CD; Hoelscher ZC; Tchakarov A; Kala J
    CEN Case Rep; 2022 Aug; 11(3):321-327. PubMed ID: 34997535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of thrombotic microangiopathies in multiple myeloma.
    Portuguese AJ; Gleber C; Passero FC; Lipe B
    Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials.
    Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S
    Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886
    [No Abstract]   [Full Text] [Related]  

  • 37. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment.
    Bilotti E
    Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Shah JJ
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
    Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
    Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carfilzomib: a novel agent for multiple myeloma.
    Redic K
    J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.